BMS-986528

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Arthritis, RheumatoidRefractorydifficult-to-treat Rheumatoid Arthritis

Phase 1

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

RecruitingNCT07412704

Bristol-Myers SquibbArthritis, Rheumatoid

Start: 2026-09-15End: 2030-09-02Target: 84Updated: 2026-08-24

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

Not yet recruitingCTIS2025-520666-22-00

Bristol-Myers Squibb Services Unlimited Companydifficult-to-treat Rheumatoid Arthritis, Refractory

Target: 18Updated: 2026-07-23